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a b s t r a c t
Insulin administration in the acute care setting is an integral component of inpatient diabetes manage-
ment. Although some institutions have moved to insulin pen devices, many acute care settings continue
to employ the vial and syringe method of insulin administration. The aim of this study was to evaluate
the impact of insulin pen implementation in the acute care setting on patients, healthcare workers and
health resource utilization.
A review of published literature, including guidelines, was conducted to identify how insulin pen devices
in the acute care setting may impact inpatient diabetes management. Previously published studies have
revealed that insulin pen devices have the potential to improve inpatient management through better
glycemic control, increased adherence and improved self-management education. Furthermore, insulin
pen devices may result in cost savings and improved safety for healthcare workers.
There are beneﬁts to the use of insulin pen devices in acute care and, as such, their implementation
should be considered.





régulation de la glycémie
utilisation des ressources en santé
malades hospitalisés/en milieu hospitalier
stylo à insuline
blessures par piqûres d’aiguilles
r é s u m é
L’administration d’insuline dans les établissements de soins de courte durée fait partie intégrante de la
prise en charge du diabète en milieu hospitalier. Bien que certains établissements aient maintenant adopté
les stylos à insuline, plusieurs établissements de soins de courte durée continuent d’utiliser la ﬁole ou la
seringue commemode d’administration de l’insuline. Le but de cette étude était d’évaluer les conséquences
de l’introduction des stylos à insuline dans les établissements de soins de courte durée sur les patients,
les travailleurs de la santé et l’utilisation des ressources en santé.
Une revue de la littérature existante, dont les lignes directrices, a été menée pour déterminer de quelle
manière les stylos à insuline dans les établissements de soins de courte durée peuvent avoir des
répercussions sur la prise en charge du diabète en milieu hospitalier. Les études précédemment publiées
ont révélé que les stylos à insuline ont le potentiel d’améliorer la prise en charge en milieu hospitalier
par le biais d’unemeilleure régulation de la glycémie, d’une observance accrue et d’unmeilleur enseignement
en matière de prise en charge autonome. De plus, les stylos à insuline peuvent entraîner des réductions
de coûts et améliorer la sécurité des travailleurs de la santé.
L’utilisationdesstylosà insulinecomportedesavantageset,dece fait, leur introductiondevraitêtreconsidérée.
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The prevalence of diabetes is increasing; a predicted 4.2 million
people will be living with diabetes by 2020. The cost of diabetes
to the Canadian economy was CAN$11.7 billion in 2010, and if dia-
betes follows current trends, this number will reach $16 billion by
2020 (1).
The Canadian Diabetes Association (CDA) estimates that 80% of
the costs result from diabetes complications. These complications
arise due to poor glycemic control and include microvascular and
macrovascular complications, such as chronic kidney disease, reti-
nopathy, neuropathy, stroke, myocardial infarction and death (2).
Diabetes is a common comorbidity in hospitalized patients (3).
Canadian practice guidelines support the need to maintain glyce-
mic control in hospitalized patients (4). A diabetes patient whose
glycemic control is inadequate during hospitalization may require
modiﬁcations of their existing diabetes treatment regimens, which
may include insulin initiation or intensiﬁcation (4).
It is imperative that every measure be taken to maintain glyce-
mic control in hospitalized patients, both during their stays and after
they are discharged, so as to minimize the risk for complications.
One potential intervention to reach this goal is the use of insulin
pen devices in both outpatient and inpatient settings.
The insulin pen device has many attributes and was developed
with the intention of improving the delivery of the drug and decreas-
ing the burden on the patient. The value of insulin pen use in the
outpatient setting has been well deﬁned (5), but a comprehensive
evaluation of the impact of using insulin pens in the Canadian acute
care setting is lacking. A conservative estimate of 12% to 26% of hos-
pitalized patients have diabetes, and inpatientmanagement of hyper-
glycemia is complex (6). Thus, outlining detailed protocols and
deﬁning the role of insulin pens in the management of inpatient
diabetes is essential.
With the prevalence of diabetes increasing and hospitalization
serving as 1 potential point of insulin initiation, it has been sug-
gested that the variousmethods of insulin administration in the inpa-
tient setting should be examined so as to beneﬁt from this unique
opportunity (7).
The goals of inpatient diabetes management have been indi-
cated as follows: achieve individual glycemic control, treat any
diabetes-related complications, prevent any drug-related adverse
events and new complications and, ﬁnally, implement education
regarding diabetes self-management (8). In addition to the afore-
mentioned goals, reducing the cost of treating diabetes is essen-
tial in the current economic climate. This review is meant to evaluate
the potential impact of insulin pen devices on the objectives of inpa-
tient management of diabetes.
Glycemic Control and Preventing Insulin-Related
Complications
Accurate dosing of insulin is important in achieving glucose targets
The clinical outcomes that contribute to the pharmacoeconomic
burden of inpatients with diabetes include hyperglycemia, hypo-
glycemia, length of stay and diabetes-related complications, such
as cardiovascular disease (8). According to recommendations by the
CDA, patients with diabetes should strive to reach glucose targets
so as to avoid or delay diabetes complications (9). In order to main-
tain optimal glycemic control, patients should be receiving the most
accurate dosages as inpatients and outpatients. Insulin pens have
been found to have consistent and accurate dose delivery across a
range of doses and within the limits speciﬁed by the International
Organization for Standardization (10).
A prospective, randomized study compared the use of insulin
pen devices and the vial/syringe method of insulin administration
in the hospital setting. Patients who were assigned to the insulin
pen group experienced fewer hyper- and hypoglycemic events daily
while using insulin pens (11). Although not statistically signiﬁ-
cant, the results suggest that pens contribute to glycemic control
in hospitalized patients.
Insulin pen devices deliver more accurate doses than vials and
syringes
One study evaluated the handling and dosing accuracy of insulin
pens vs. vials and syringes involving both insulin therapy-naive and
insulin therapy-experienced healthcare professionals (nurses and
pharmacists) (12). Insulin therapy-naive healthcare professionals
found that the insulin pen was both easier to hold and more stable
during injection (p<0.01). For both groups of healthcare profes-
sionals, the insulin penmean dose delivered was signiﬁcantly closer
to the intended dose of 10 U than the dose delivered via vial and
syringe (p<0.001) (12). It should also be noted that the syringe and
vial methods demonstrated higher degrees of variation in doses
delivered than the insulin pen, as demonstrated by the differ-
ences in standard deviation from the mean (12).
A similar study of the performance of healthcare professionals
in the United States, including physicians, diabetes nurses and edu-
cational and institutional nurses, reported comparable results. The
mean absolute deviations of the insulin doses administered by
healthcare professionals were signiﬁcantly reduced when using
insulin pens compared to vials and syringes (p<0.0001) across 4 dif-
ferent doses (5 IU, 25 IU, 43 IU, 78 IU) (13).
Injection technique and use of shorter needle length are
recommended to ensure optimal insulin delivery
In addition to achieving tight glycemic control through accu-
rate dosing, the depth of injection should also be considered
(Figure 1). It has been suggested that injection technique holds sig-
niﬁcance comparable to that of dose and insulin type in achieving
glycemic control (14). For optimal absorption of insulin, injection
into the subcutaneous tissue is recommended (15). The speed of
insulin diffusion depends on the depth of injection. If insulin is
injected too deeply, the rapid diffusion results in a shorter dura-
tion of action, and these intramuscular (IM) injections result in a
broader variability of absorption (16).
An evaluation of skin thickness and subcutaneous adipose layer
thickness by ultrasound was conducted in adult patients with dia-
betes and with a range of adiposity and diverse demographic char-
acteristics. The mean skin thickness ranged from 1.87 mm in the
thigh to 2.41 mm in the buttocks. The mean subcutaneous adipose
layer thickness ranged from 10.35 mm in the thigh to 15.45 mm in
the buttocks (14). The authors estimated, based on their ﬁndings,
the percentage of injections that would result in subcutaneous (SC)
vs. skin or IM drug delivery. It was estimated that using 5 mm
needles, 98% of 90 degree insertions are SC and the remainder IM;
6 mm and 8 mm needles showed that proportionately more injec-
tions are IM (>5% and 15%, respectively); and 12.7 mm needles
showed that 45% of injections would be IM. The use of a 4 mm
needle was estimated to deliver drug SC 99.5% of the time (14).
Insulin syringes are available as short as 6 mm, whereas safety pen
needles are available at 5 mm, and nonsafety pen needles are avail-
able at 4 mm.
Reducing the risk for adverse events related to insulin administration
Nurses administering insulin are at risk for experiencing a
needlestick injury
A retrospective study in the United States evaluated needlestick
injuries to nurses in diabetes care and found that 313 of 400 (78.3%)
ARTICLE IN PRESS
C. Smallwood et al. / Can J Diabetes xxx (2016) 1–62
nurses had experienced needlestick injuries, with 110 (27.5%) having
experienced at least 1 needlestick injury within the past 12 months
(17). The needlestick injury that occurred most commonly occurred
with insulin injections (30.0%). Notably, a reported 80% of the inju-
ries involved disposable syringes (compared to winged-needle intra-
venous sets, vacuum tubes and blood-collection needles) (17).
Using an insulin pen can reduce the risk for needlestick injuries and
their associated costs
The passive, dual-ended safety technology available for insulin
pen needles inherently gives them an advantage over the tradi-
tional active safety features for syringes. Thus, it follows that when
moving from traditional safety syringes to insulin pen devices with
passive safety-engineered needles, a reduction in needlestick inju-
ries would be observed. A retrospective study evaluating needlestick
injuries associated with various devices found 2.71 needlestick inju-
ries per 100 000 safety injection devices comparedwith 0 needlestick
injuries per 100 000 insulin pens with safety needles (18).
In a pilot study that evaluated the impact of an interchange
program (conventional vial/syringe to disposable, single-ended safety
pen device), only 1 staff needlestick injury occurred in the 6 months
postimplementation, compared with 5 injuries during the
preimplementation period, an 80% reduction (19). A Canadian pilot
study evaluating the impact of insulin pens in hospital settings found
that 21.2% of nurses preimplementation experienced a needlestick
injury (either reported or unreported) compared to 2.6% of nurses
postimplementation (20).
A study evaluating insulin pen devices found that pen needles
with automatic recapping capabilities resulted in a signiﬁcant reduc-
tion in accidental punctures when administering insulin to another
individual (p<0.001) (21). Furthermore, a study evaluating the ability
of safety pen devices to protect nurses found that of the 28
needlestick injuries, the majority resulted from nurses recapping
needles or assisting patients in recapping their needles (22). Although
the safety pen needles are associated with an increase in cost, a
reduction in injuries was observed since implementation of safety
pen needles, and this translated to a cost beneﬁt for the pens of a
14% saving (22).
Needlestick injuries are burdensome to the healthcare system and
professionals
A needlestick injury can be burdensome to healthcare workers
and the institutions in terms of emotional and psychological effects
on the individual as well as time lost and cost to the healthcare
system. In Canada, the cost of a needlestick injury follow up is
approximately $500, though if the exposure is high risk (i.e. the
potential to acquire HIV or hepatitis) this cost could increase by
$1500, for a total of $2000, including prophylaxis (23). Indirect costs
of compensation for time lost were calculated to be approxi-
mately $6000 (23).
In Quebec, the direct costs have been estimated to range from
$272.16 (medium risk) to $2057.75 for high-risk cases, adding up
to $6030.52 to account for the additional costs related to absence
from work (24).
Medication errors related to insulin occur frequently and may
compromise patient safety
A prospective study in 14 acute care hospitals in Ontario found
that insulin was among themost commonly involved individual drug
in medication errors (188 insulin errors in a 12-month period) (25).
Furthermore, it was determined that errors occurred most com-
monly during the administration process (56.6%), and improper dose
accounted for 25.7% of the process errors (25). A second study, in
the United States, found similar rates of error: 61% of errors occurred
during insulin administration, and 26% of errors involvedwrong dose,
strength or frequency (26).
A study by the Institute for Safe Medication Practices found that
insulin is among the top medications commonly involved in errors,
with 11% of all errors recorded involving insulin (27). Errors in insulin
administration can result in severe adverse events and poor gly-
cemic control in hospitalized patients which, in turn, can result in
complications and the costs associated with increased lengths of
hospitalization (28). The Canadian Diabetes Cost Model predicts that
by 2020, patients with diabetes will spend 5.4 million days in the
hospital (9). It is critical that the potential for error be minimized
so that the correct dose is given at the correct time, in order for
glycemic control to be achieved.
Adherence: Educating Patients with Diabetes for
Self-Management
As suggested by Wexler et al, hospitalization presents unique
opportunities to impact glycemic control in the long term, when
considering a health systems point of view, because hospital admis-
sion identiﬁes patients with diabetes at highest risk for uncon-
trolled diabetes, complications and costs (29). Thus, it is imperative
that for insulin-treated inpatients, adequate planning for the tran-
sition of care from hospital to home be required to ensure that
patients manage changes in treatment regimens (4,30,31).
The CDA and American Diabetes Association practice guide-
lines suggest that discharge planning should include in-patient dia-
betes self-management education to teach patients the essential
“survival skills” to begin insulin therapy (4,30). If diabetes is not
managed adequately postdischarge, patients are at risk for poor out-
comes, including rehospitalizations (29).
Adherence is associated with improved glycemic control
Adherence is deﬁned as both compliance and persistence:
patients must comply with the correct doses at the prescribed
Figure 1. Schematic of the value of the insulin pen device in glycemic control. Indi-
vidualized glycemic control is crucial for patients with diabetes in order to reduce
complications, lengths of stay and hospital costs and to increase quality of life. Insulin
pen devices increase dose accuracy, which leads to the correct dose being admin-
istered. The shorter needle length reduces the number of intramuscular injec-
tions, leading to better absorption of insulin.
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intervals andmust persist for the appropriate durations of time (32).
A review of the literature by Asche et al found that most studies
(56.5%) found a signiﬁcant association between improved adher-
ence and better glycemic control (32). In the Canadian context,
approximately 5.4% of all hospitalizations are due tomedication non-
adherence, costing between $687 million and $1.6 billion annu-
ally (33).
Low adherence rates in patients with diabetes increase the likelihood
of diabetes-related complications and healthcare costs
A meta-analysis reporting on adherence to medical treatment
determined that diabetes was ranked among the lowest for adher-
ence. This study found the average rate of nonadherence to be 24.8%
(34). A systematic review of insulin adherence in patients with type 2
diabetes found an adherence rate of 62% to 64% (nonadherence of
36% to 38%) (35). Other authors have estimated that the rate of non-
adherence to diabetes drugs lies at approximately 31.4% (36).
Lack of adherence by patients with diabetes results in a 59%
increased likelihood of kidney complications and a 66% likelihood
of dying from diabetes-related causes (32). Furthermore, it was found
that each 10% increase in adherence to antidiabetic agents results
in a mean decrease of hospitalizations by 6.6% and an 8.6% decrease
in total annual healthcare costs (p<0.05) (37). Higher medication
possession ratios (MPRs) were associated with lower costs, inde-
pendent of medication type (insulin vs. oral agents) (37).
Kleinman et al found that only 36.5% of insulin users were, at a
minimum, 80% compliant, and that medical costs (excluding pre-
scription drug costs) were signiﬁcantly lower whenMPRs were high
(38). For example, in the patients who had high costs, patients with
100% MPRs had $6653 in medical costs compared to $11 763 for
those with MPRs of 10%. Thus, by increasing adherence, there is a
potential for signiﬁcant cost savings (38).
With evidence of this relationship, it would be advantageous to
take measures to increase adherence within the patient population.
Insulin pen devices are associated with greater adherence, fewer
hypoglycemic events and lower healthcare costs
A study looking at adherence through MPRs found that a sig-
niﬁcantly higher proportion of patients were adherent (MPRs >80%)
with the implementation of insulin pen devices for patient use
(p<0.01) (39). In addition, adherence was associated with reduc-
tions in hypoglycemic events (p<0.05), and the all-cause health-
care costs per patient decreased signiﬁcantly after the
implementation of the insulin pen, of which diabetes-related costs
comprised approximately 62% of the total healthcare costs. Cost
decreases were associated with decreased emergency depart-
ment visits (7.4 vs. 5.2 visits; p<0.01); hospital lengths of stay (9.6
vs. 6.4 days; p<0.01); and physician visits and pharmacy costs (39).
Insulin pen devices are rated higher in terms of patient preference
In a multicentre, randomized, open-label, 2-period crossover trial
comparing patient preference between the vial/syringe method and
the insulin pen device, it was found that 74% of patients indicated
a preference for the pen, and only 20% preferred the vial/syringe
method (40).
The standards set by the National Institute for Health and Care
Excellence (NICE), a UK guidance body recognized internationally
for adults with diabetes state that patients should have the option
of self-monitoring their blood glucose levels and self-administering
subcutaneous insulin (41). It was found that patients receiving insulin
via the pen device during their hospitalizations were more likely
to continue administering insulin at home with this method and
to recommend pens to other patients for insulin administration
during hospitalization compared to the vial and syringe (p<0.05)
(11).
Insulin pen devices are rated higher in terms of ease of teaching and
learning, a critical component in patient education for self-
management
Effective education of patients with diabetes while in the hos-
pital is crucial in the process of patient self-management. A study
evaluating patient, caregiver and healthcare professional prefer-
ences found that using an insulin penwas rated by signiﬁcantlymore
subjects as easier to teach (healthcare professionals) and easier to
learn (patients and caregivers) (13). Interestingly, signiﬁcantly more
patients in the pen group self-administered insulin during their hos-
pital stays compared to the vial and syringe group (11).
In a study comparing physician, nurse and patient perceptions
of the pen vs. the vial/syringe, the pen was preferred signiﬁcantly
over the vial/syringe for teaching (p<0.001) and for learning to use
(p<0.001) (42); 100% of nurses and 87% of physicians preferred the
pen to the vial/syringe for ease of teaching (42).
In addition to ease of teaching and learning, it has been reported
that recommendation of the use of insulin pens (not simply the pre-
sentation of pens as an option) by a physician was a powerful
differentiator betweenwhich patients use and do not use pens (odds
ratio, 135.6) (43).
Reducing diabetes-related ineﬃciencies and cost
With the rising cost of diabetes, it is essential that ineﬃcien-
cies be identiﬁed and targeted to reduce wasteful healthcare spend-
ing. The Public Health Agency of Canada (PHAC) reported results
from a study in Saskatchewan that compared per capita costs for
people with and without diabetes. The results demonstrated that
the costs for those with diabetes nearly tripled in the ﬁrst year after
diagnosis. PHAC indicated that this was most likely due to the nec-
essary hospital care at initial diagnosis. After the initial spike, there
were minor cost increases, which reﬂect medication costs, day sur-
geries and dialysis (44).
In addition to the costs associated with needlestick injuries as
they relate to insulin administration, insulin waste and nursing time
may also be positively impacted by the use of insulin pen devices.
Reducing insulin waste is important not only to curb health-
care costs, but in an era of drug shortages and a global focus on the
environment and sustainability, an effort should be made to reduce
insulin waste and the volume of discarded administration sup-
plies. A study involving 5 Ontario hospitals found that an average
34.1% of insulin from vials waswasted (35.6% in the acute carewards)
(45). Insulin waste was due largely to expiration (73.9%), with the
remaining waste due to patient discharge and spoilage (45). In this
1994 study, the authors recommended that “[hospitals] should esti-
mate their insulin wastage and seek ways to reduce it. The phar-
maceutical industry should be encouraged to develop cost-effective
insulin delivery systems” (45).
A study in 36 hospitals evaluated how nurses spend their time
and found that nurses spend 17.2% of their nursing practice time
administeringmedications (46). The authors concluded that “because
nurses devote considerable time to this category of care, opportu-
nities may exist to improve eﬃciency” (46). Due to the nature of
insulin pen devices (i.e. preﬁlled cartridges and dose dialing), the
time for nurses to draw the correct dose and administer to the
patient may be reduced.
Converting to insulin pen devices results in overall cost savings to the
institution
There have been demonstrated cost savings after conversion to
insulin pen devices in hospitals. An interchange program to evaluate
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the impact of pen devices at a 214-bed hospital found that the total
cost of insulin products before implementation was $124 181, com-
pared to $60 655 after implementation (19). Another study evalu-
ating the ﬁnancial consequences of insulin pen devices compared
to the vial/syringe found a projected cost saving of $36 per patient
if insulin pens were dispensed during the entire hospital
stay (11).
Summary
Insulin pen devices are currently used in the outpatient setting
and, at times, in the acute care setting. A multitude of published
studies and unpublished pilot studies have demonstrated the value
of implementing pen devices and a safety pen needle in hospitals.
The beneﬁts include reducing the risk for adverse events, such as
needlestick injuries and medication errors, and achieving tighter
glycemic control as a result of shorter needle length availability
(reduction in intramuscular injections and improved adherence).
Insulin pen devices in the acute care settingmay also decrease waste
and ineﬃciencies, such as insulin waste and nursing time, though
further research in these areas is warranted (Figure 2).
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